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Abstract
Objective To determine the relative effectiveness of second generation
ablation techniques in the treatment of heavy menstrual bleeding.
Design Network meta-analysis on the primary outcome measures of
amenorrhoea, heavy bleeding, and patients’ dissatisfaction with
treatment.
Data sources Nineteen randomised controlled trials (involving 3287
women) were identified through electronic searches of the Cochrane
Library, Medline, Embase and PsycINFO databases from inception to
April 2011. The reference lists of known relevant articles were searched
for further articles. Two reviewers independently selected articles without
language restrictions.
Eligibility criteria for selecting studies Randomised controlled trials
involving second generation endometrial destruction techniques for
women with heavy menstrual bleeding unresponsive to medical
treatment.
Results Of the three most commonly used techniques, network
meta-analysis showed that bipolar radiofrequency and microwave
ablation resulted in higher rates of amenorrhoea than thermal balloon
ablation at around 12 months (odds ratio 2.51, 95% confidence interval
1.53 to 4.12, P<0.001; and 1.66, 1.01 to 2.71, P=0.05, respectively), but
there was no evidence of a convincing difference between the three
techniques in the number of women dissatisfied with treatment or still
experiencing heavy bleeding. Compared with bipolar radio frequency
and microwave devices, an increased number of women still experienced
heavy bleeding after free fluid ablation (2.19, 1.07 to 4.50, P=0.03; and
2.91, 1.23 to 6.88, P=0.02, respectively). Compared with radio frequency
ablation, free fluid ablation was associated with reduced rates of
amenorrhoea (0.36, 0.19 to 0.67, P=0.004) and increased rates of
dissatisfaction (4.79, 1.07 to 21.5, P=0.04). Of the less commonly used
devices, endometrial laser intrauterine thermotherapy was associated
with increased rates of amenorrhoea compared with all the other devices,
while cryoablation led to a reduced rate compared with bipolar radio
frequency and microwave.
Conclusions Bipolar radio frequency and microwave ablative devices
are more effective than thermal balloon and free fluid ablation in the
treatment of heavy menstrual bleeding with second generation
endometrial ablation devices.
Introduction
Heavymenstrualbleedingisacommonincapacitatingproblem
in women of reproductive age,
1 which can severely affect their
quality of life.
2 3 When medical treatments fail to provide
adequate relief, surgical interventions, including hysterectomy
ordestructionoftheendometrium,canbeconsidered.
4Initially,
rollerball ablation, transcervical resection, and laser ablation
were the predominant endometrial destruction techniques
performed under direct hysteroscopic vision. These led to a
rapid decrease in the number of hysterectomies performed.
5
Overthepastdecade,asecondgenerationofnon-hysteroscopic
techniques, which are safer, technically easier to perform,
involveshorterhospitalstays,andcanbeperformedunderlocal
anaesthesia, have become dominant.
6 7 These involve devices
thataresitedandactivatedtotreatthewholeendometrialcavity.
Destruction is achieved through various methods, the most
commonlyused
8beinghightemperaturefluidswithinaballoon
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Research
RESEARCH(Thermachoice and Cavaterm)
9-11 or application of microwave
(Microsulis)
12 13 or bipolar radiofrequency electrical energy
(Novasure).
14 Less commonly used ablative techniques include
freefluidathightemperature(Hydrothermablator),
15endometrial
laser intrauterine thermotherapy (ELITT),
16 and cryoablation
(HerOption).
17 Other than free fluid thermal ablation, these are
“blind”techniques.Arecentmeta-analysisofindividualpatient
data found that second generation techniques were at least as
effective,intermsofpatients’dissatisfaction,asfirstgeneration
techniques and, importantly, gave rise to fewer operative
complications, were considerably quicker, and were less likely
to need to be performed under general anaesthesia.
18 Thus they
are clearly preferable to first generation techniques.
When more than two treatments options are available, the use
of network meta-analysis, which allows us to combine both
direct and indirect estimates for treatment effects, has become
increasinglycommon.
19 20Randomisedcomparisonswithintrials
are preserved and the main assumption—that there are no
systematic differences between the trials that could bias the
indirect measurements—is similar to those underlying any
standard meta-analysis.
There have been numerous randomised controlled trials
comparingthedifferentsecondgenerationtechniqueswitheach
otherorwithfirstgenerationdevices,yetwiththesheernumber
of potential comparisons there are gaps in direct evidence for
efficacyofsometechniques,whileothercomparisonshavelow
statisticalpowerbecauseofthesmallnumbersrandomised.We
carried out a network meta-analysis to assess the relative
effectiveness of six second generation techniques to provide
both users and recipients of these devices with an improved
evidence base to inform their decision making.
Methods
The systematic review was conducted based on a protocol
designed with widely recommended methods
21 22 that complied
with reporting guidelines for meta-analyses.
23
Literature search and study selection
We carried out an extensive literature search in the Cochrane
Library, Medline, Embase, and PsycINFO from inception to
April 2011. Our search term combinations consisted of MeSH
subheadings, text words and word variations for “heavy
menstrual bleeding,” and the various types of first and second
generation endometrial destruction techniques. This search
strategy was adapted to suit each database and was restricted to
“humans” and “females” (see appendix 1). Bibliographies of
known relevant primary articles and reviews were searched by
handtoidentifyarticlesmissedbytheelectronicsearches.Were
also contacted experts in the specialty to uncover any grey
literature. A comprehensive database was constructed with
Reference Manager 12.0 to store all identified references. No
language restriction was applied.
Studies were selected in a two step process. Firstly, we
scrutinised the citations identified by the electronic searches
andsubsequentlyobtainedfullmanuscriptsofcitationsthatmet
orwerethoughttohavemetthepredeterminedinclusioncriteria.
We included studies if they recruited women with heavy,
abnormal, excessive, or prolonged uterine bleeding that was
unresponsive to initial medical treatment and the study design
was a randomised controlled trial comparing endometrial
ablation methods.
Data collection and study quality assessment
Two reviewers (LJM and RC) independently inspected all the
manuscripts to determine if they met the above criteria. When
possible we obtained individual patient data from the primary
author using methods described in the related meta-analysis.
18
When raw data were not available, two independent reviewers
(RCandLJM)usedpredesignedformstoextractaggregatedata
from manuscripts. Any disagreements were resolved by
consensus or arbitration by a third reviewer (JPD).
Outcome measures used to evaluate the treatments were those
most commonly used across studies (table 1⇓): rate of
amenorrhoea (converted from a pictorial bleeding assessment
score of zero when these data existed, otherwise as reported),
rate of heavy bleeding (likewise converted from a pictorial
bleeding assessment score of >100
24 when data existed,
otherwiseasreported),andrateofdissatisfactionwithtreatment
(see related paper for a full description of how dissatisfaction
was calculated).
18 We used data at 12 months (the most popular
time point) as the focus for analysis or results at two years if 12
month data were not available.
Statistical analysis
For all three outcomes we first assessed direct estimates in
individual trials by calculating point estimates and 95%
confidence intervals. We then calculated a traditional weighted
average meta-analysis yielding a Mantel-Haenszel odds ratio,
with heterogeneity investigated with Cochran’s Q
25 and I
2
statistics.
26
We carried out the network meta-analysis by fitting a linear
mixed model to the log odds ratio from each trial with the
GLIMMIX procedure in SAS, using maximum likelihood to
estimatetreatmenteffects.Twomodelswereattempted;thefirst
included a fixed treatment effect and allowed the effect of the
study to vary randomly. The second model also included a
random effect for the difference in treatment in each trial by
including a study by treatment interaction parameter.
27 The
inclusion of a random study effect allowed the recovery of any
differences between trials, which has greater importance when
notallofthetreatmentsareincludedineverytrial,asisthecase
here.
28Wealsoincludedarandomeffectfortreatmentpair(that
is,toseparatethosetrialscomparingdifferenttreatmentstypes)
in both models to allow for any inconsistency or “incoherence”
in the model.
29 This effect (ω, the standard deviation of the
random effect) allows for any indirect estimates to be
inconsistent with any direct estimates of the same treatments
and can be calculated where there any closed “loops” of
treatments exist (for instance, A v B, B v C, A v C). Increased
incoherence increases standard errors, and hence the size of the
confidence interval, of differences between treatments. If large
levels of incoherence are present it might not be sensible to
combineestimateswiththismethod,
30analogoustohavinghigh
levels of heterogeneity in a standard meta-analysis. We used
Revman v5.0 (Cochrane Collaboration, Denmark) and SAS
v9.2 (SAS Institute, Cary, NC) software for analysis.
Results
Trials and patients
We identified 719 citations through the electronic literature
searches (fig 1⇓) and excluded 672 after screening titles and
abstracts. A further 28 were excluded for being duplicate
publicationsornotinvolvingdirectcomparisonsofendometrial
ablative techniques. After detailed evaluation of the citations,
19 primary articles met the selection criteria and were included
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RESEARCHin the network meta-analysis (see appendix 2 for full details of
these 19 studies). These consisted of five head to head
comparisonsofsecondgenerationdevices
31-35(744women)and
14comparingasecondgenerationdevicewithafirstgeneration
(hysteroscopic) device
9 12 14-17 36-43 (2543 women) (fig 2⇓). Table
1 shows further descriptions of device type and the frequencies
used in the analysis⇓. As the fixed and random effect network
meta-analysis models produced similar results only those from
the latter are described here.
Effectiveness in reducing bleeding
Directcomparisonsshowanincreasedrateofamenorrhoeawith
bipolarradiofrequencyablationcomparedwiththermalballoon
ablation (odds ratio 4.56, 95% confidence interval 2.24 to 9.26;
P<0.001) (table 2⇓). Free fluid thermal ablation was associated
withreducedratesofamenorrhoea(0.36,0.18to0.73;P=0.005)
and increased rates of heavy bleeding (4.88, 1.32 to 18.11;
P=0.02, table 3⇓) compared with bipolar radio frequency
ablation.Wefoundnootherconvincingdifferences.Whenthere
was more than one study in a comparison, estimates between
studies were highly consistent (all I
2=0% apart from the
comparison of amenorrhoea rates with microwave ablation
versus first generation techniques where I
2=17%).
Results from the network meta-analysis (tables 2 and 3 and fig
3⇓) concurred with the results of the direct evidence, with an
increased rate of amenorrhea with bipolar radio frequency
ablation compared with thermal balloon ablation (2.51, 1.53 to
4.12; P<0.001). Results were also similar for the comparison
betweenfreefluidthermalablationandbipolarradiofrequency
ablation for amenorrhoea (0.36, 0.19 to 0.67; P=0.004) and
heavy bleeding (2.19, 1.07 to 4.50; P=0.03). There was an
increaseintherateofamenorrhoeawithradiofrequencyablation
compared with cryoablation in the indirect comparison (0.20,
0.09to0.49;P=0.002).Microwaveablationwasassociatedwith
anincreasedrateofamenorrhoeacomparedwiththermalballoon
ablation (1.66, 1.01 to 2.71; P=0.05) and cryoablation (0.31,
0.13 to 0.74; P=0.01) and some reduction in the rate of heavy
bleeding compared with free fluid ablation (2.91, 1.23 to 6.88;
P=0.02). The endometrial laser intrauterine thermotherapy
(ELITT) was associated with increased rates amenorrhoea
compared with all the other devices, with wide confidence
intervals reflecting the small number of women evaluated with
this device in randomised controlled trials (table 2⇓). No other
compellingdifferencesbetweendeviceswerenoted.Therewere
relatively low but variable rates of heavy bleeding across the
studies (such as 0-32% for thermal balloon ablation and 8-18%
for bipolar radiofrequency ablation).
Effectiveness in reducing dissatisfaction with
treatment
Direct comparisons showed some evidence of reduced rates of
dissatisfaction with bipolar radio frequency ablation compared
withthermalballoonablation(0.39,0.16to0.91;P=0.03)(table
4⇓),thoughthisdifferencewasnotasconvincinginthenetwork
meta-analysis (0.56, 0.28 to 1.09; P=0.09). Increased
dissatisfaction was seen with free fluid thermal ablation
compared with bipolar radio frequency (9.40, 1.14 to 77.18;
P=0.04) and a similar result was seen in the network
meta-analysis(4.79,1.07to21.48;P=0.04).Therewerenoother
obviousdifferences.Directestimatesbetweenstudieswerealso
consistent for dissatisfaction where more than one study in a
comparisonexisted(0%<I
2<4%).Overallratesofdissatisfaction
were generally low (such as 0-7% for bipolar radiofrequency
ablation).
Incoherence
Estimates of incoherence, ω, from the network model of
amenorrhoea rate were relatively high at 0.23 compared with
other studies that have used this technique to evaluate multiple
treatments simultaneously.
19 30 44 When we removed the single
trial comparing microwave ablation with thermal balloon
ablation,
33 this estimate was reduced to 0.13. This trial’s direct
estimate yielded no significant difference between treatments
(1.13, 0.70 to 1.82; P=0.6), which conflicted with the estimate
expectedbyanyindirectcomparisonwherethenetworkanalysis
favoured microwave ablation (1.66, 1.01 to 2.71; P=0.05). A
sensitivity analysis of the network analysis with this trial
excluded produced a higher estimate in favour of microwave
ablation (2.23, 1.21 to 4.09; P=0.02), with some other minor
adjustments to the other estimates (free fluid ablation was now
associated with a lower amenorrhoea rate also compared with
microwave ablation: 0.45, 0.21 to 0.97; P=0.04). Incoherence
parameters for heavy bleeding and dissatisfaction, along with
theinteractionparameterforstudybytreatment,wereestimated
tobesoclosetozerothattheywerenegligibleandsoeffectively
did not contribute to any estimates.
Discussion
Main findings
Of the three most popular second generation endometrial
ablation devices (thermal balloon, bipolar radio frequency, and
microwave) examined in this network meta-analysis, bipolar
radio frequency and microwave ablation techniques seem to
have an advantage over thermal balloon ablation in terms of
increased amenorrhea rate in women with heavy menstrual
bleeding. Compared with free fluid ablation, both bipolar radio
frequency and microwave ablation techniques were associated
with a reduction in the number of women still experiencing
heavy bleeding. Radio frequency ablation was also associated
with an increased amenorrhoea rate and a reduced number of
women dissatisfied with treatment compared with free fluid
ablation.Endometriallaserintrauterinethermotherapy(ELITT)
was also associated with high rates of amenorrhoea compared
with hysteroscopic ablation in the small single study that
evaluated this technique. Not surprisingly this translated to
estimates of amenorrhoea higher than the other devices when
wecombinedresultsinthenetworkmeta-analysis.Conversely,
cryoablation was associated with lower rates of amenorrhoea
comparedwithbipolarradiofrequencyandmicrowaveablative
techniques. Rates of dissatisfaction with treatment or ongoing
heavy bleeding were generally low across all studies. Apart
from the comparison of microwave ablation versus thermal
balloonablation,estimatesfromthenetworkmeta-analysiswere
consistent with available direct estimates between second
generation devices in terms of direction and significance of
treatmenteffect.Theimplicationofthisinconsistencyfromthis
one comparison is unclear.
Strengths and limitations of the review
We used the relatively new approach of network meta-analysis
tosynthesisedata,andthisprovidedeffectestimateswhendirect
comparisons were not available. We used optimal methods,
complying with guidelines on reporting of systematic reviews
and meta-analyses.
23 We carried out an extensive literature
search, with no language restrictions, minimising the risk of
missing information. The collection of individual patient data
from some studies improved estimates.
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RESEARCHThe review was not intended to be a comprehensive review of
all facets of these devices, and we focused only on outcomes
of bleeding after treatment reported by patients and patients’
dissatisfaction with treatment. Many other factors, such as ease
ofuseandsafetyofdevice,aretakenintoaccountinthedecision
regardingaparticulardevice.Forexample,thetimetocomplete
treatment is significantly shorter with bipolar radiofrequency
ablation, and it results in greater coverage of the endometrial
surface than thermal balloon ablation, in an outpatient setting.
31
Because of the limited amount of data (several comparisons
consisted of only one trial) and the fact that the traditional
meta-analysis did not show any evidence of heterogeneity
between estimates (I
2 was generally 0% and never greater than
17%) we did not attempt to further subgroup results by
manufacturer or type (Thermachoice, Cavaterm, and the
discontinued Vesta all are types of thermal balloon ablative
device). This consistency could have occurred by chance, and
therecouldbesomedifferencesbecauseofthedesignofsimilar
products. This could be reasonably evaluated only should more
data become available. We considered that the first generation
ablative techniques of transcervical endometrial resection and
rollerball electrocoagulation were equivalent so we used them
as a generic intermediate comparator.
45 46
Estimates of incoherence were relatively high for the analysis
of amenorrhoea rate (less when we omitted one of the studies
in a sensitivity analysis), though how this impacts on adjusted
estimates is debatable, given that confidence intervals of
estimates were increased as a result. Like all meta-analysis, we
must consider limitations with combining estimates from
different studies because of clinical heterogeneity such as
differences in populations of patients, even with statistical
adjustments in the analysis. For example, the small study that
comparedendometriallaserintrauterinethermotherapy(ELITT)
with first generation techniques seemed to show a large
treatmenteffect.Giventhatnoneoftheotherstudieshasshown
a comparable effect, there could be something particular about
this study, such as the lower rate of amenorrhoea for the first
generation comparator, that separates it from the rest, but in the
absence of raw data, we were unable to investigate this further.
Conversely, the absence of a significant difference does not
necessarily mean that techniques are comparable but could be
a consequence of small underpowered trial populations. This is
reflectedinwideconfidenceintervalsforsomeoftheestimates.
We did not take into account quality of study in these analyses;
theonlyrequirementwasthatthestudyneededtoberandomised
in a specified population of patients.
The usefulness of the network meta-analysis in this setting was
highlighted during the course of this review when we updated
the analysis to include the results of the most recent study of
bipolar radio frequency and free fluid endometrial ablation
32;
the first to compare these two treatments directly. Results from
this study for the primary outcome measure of amenorrhoea
rateat12monthssuggestedimprovementswithradiofrequency,
with an odds ratio of 0.36 (0.17 to 0.73). Before inclusion of
this later study, our original estimated odds ratio from the
network meta-analysis was 0.33, which is similar albeit with a
slightly wider confidence interval (0.11 to 0.98). Such an
accurate estimate could of course occur by chance, but it does
show how useful this analytical method could be where direct
head to head assessments of treatments are not available.
Interpretation
Ratesofdissatisfactionandheavybleedingareconsistentlylow
for second generation techniques, which, as a group, represent
anexcellentconservativealternativetohysterectomy.Itisclear
from the results of our review that bipolar radiofrequency and
microwave ablation technique are associated with higher
amenorrhea rates than other methods, although it should be
reiterated that only hysterectomy can guarantee complete
cessation of menstrual bleeding. Endometrial laser intrauterine
thermotherapy (ELITT) was associated with highly significant
improvements in amenorrhea rates compared with all other
methods,albeitfromonesmallstudy,butthisdeviceisnolonger
marketed (C Dunn, Karl Storz, personal communication).
Data from UK hospital episode statistics show a significant
increaseintheoverallnumberofinpatientendometrialablative
techniques (fig 4⇓), though radiofrequency ablation techniques
are recently the most rapidly rising techniques used. These data
donotincludeambulatoryprocedures,whicharealsoincreasing
rapidly but not adequately coded in the hospital episode data.
Morerecently,themicrowaveendometrialablationsystemfrom
MicrosulishasbeenwithdrawnfromtheEuropeanmarketafter
Hologic acquired the intellectual property for the device
(Microsulis Medical, press release, 2011). Ambiguous
categorisation of first generation techniques in the episode data
precludes comparison of relative rates, but consensus is that
such techniques have rapidly been superseded.
With respect to costs and cost effectiveness, one study has
directly compared thermal balloon and microwave ablative
techniques.
47 The mean total health service cost per patient was
£181 (£70 to £434) more (equivalent to about €219, $287) for
the thermal balloon system than for the microwave ablative
device (at 2010 costs), though the study found no significant
differencesbetweenthetotalnon-healthcostsandhealthbenefits
of the two devices. The incremental cost effectiveness ratio
showed microwave ablation, on average, dominated thermal
balloon ablation at one year after the procedure.
Ourpreviousreviewindicatedthatlevelsofdissatisfactionwith
second generation techniques, as a class of procedure, were
slightly lower than those associated with first generation
techniques. Second generation techniques were also quicker,
associated with faster recovery times and fewer adverse
procedural events, and could be carried out under local
anaesthesia.
18 Thus they should be offered when no structural
or histological abnormality is present and the woman wants to
retain her uterus. While chances of pregnancy are reduced after
endometrialablation,theycanoccurandsuchpregnancieshave
ahighriskofadverseoutcomes,hencecontinuedcontraception
is strongly advised.
48
As to the question of the best second generation technique,
bipolar radiofrequency ablation seems to offer benefits over
thermalballoonintermsofamenorrhearatesandisprocedurally
quicker than thermal balloon and microwave ablation.
31 33-35.
Any impact on other outcomes was not significant in either
direct comparisons or network meta-analysis. Only two studies
have evaluated the use of these three devices under local
anaesthesia,
31 33 so while outpatient hysteroscopic treatment is
feasible,itwouldbeprematuretostateanyadvantageforeither
anaestheticapproach.Thedecisionshouldbelefttothewomen’s
preferenceandtheoperator’sexperience,thoughthewithdrawal
of the microwave ablation device reduces available choices.
Further large scale rigorous randomised trials to compare
existingandemergingablativetechniquesshouldusemeaningful
andstandardisedmeasuresofsatisfactionandmenstrualbleeding
andberunindependentlyfromthemanufacturersofthedevices.
Trials incorporating different anaesthetic approaches will also
help to refine the evidence available to women and
gynaecologists.Concernswithregardtothesafetyofthe“blind”
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RESEARCHtechniques with respect to extrauterine injury should lead to
furtherevaluationofvisualablativetechniquessuchasthenext
generation of free fluid ablation. Adequate assessment of
relatively rare adverse events, however, would require large
cohorts similar to the MISTLETOE study.
49
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RESEARCHTables
Table 1| Characteristics of included trials and event rates for amenorrhoea, heavy bleeding, and dissatisfaction in systematic review and
network meta-analysis of second generation endometrial destruction techniques for heavy menstrual bleeding
Dissatisfaction rate Heavy bleeding rate Amenorrhoea rate
Treatment device
(manufacturer/trade
name)
Primary
outcome
measure Study
1st
generation
2nd
generation
1st
generation
2nd
generation
1st
generation
2nd
generation
Studies comparing second generation treatments
— 2/28 — 2/25 — 14/25 Bipolar radio frequency
(NovaSure)
Amenorrhoea
rate
Clark 2011
31
— 6/32 — 6/26 — 6/26 Thermal balloon
(Thermachoice)
— 1/75 — 8/75 — 35/75 Bipolar radio frequency
(NovaSure)
Amenorrhoea
rate
Penninx
2010
32
10/71 — 10/71 — 17/71 Free fluid (BEI Medical
Systems)
— 35/144 — 6/149 — 61/149 Microwave (Microsulis) Satisfaction rate Sambrook
2009
33
— 31/134 — 7/134 — 51/134 Thermal balloon
(Thermachoice)
— 8/83 — 14/79 — 34/79 Biploar radio frequency
(NovaSure)
Amenorrhoea
rate
Bongers
2004
34
— 8/43 — 7/38 — 3/38 Thermal balloon
(Thermachoice)
— 0/34 — 5/37 — 16/37 Biploar radio frequency
(NovaSure)
Amenorrhoea
rate
Abbott 2003
35
— 1/15 — 0/17 — 2/17 Thermal balloon (Cavaterm)
Studies comparing second generation treatments with first generation hysteroscopic devices
3/16 2/21 2/17 2/30 5/17 11/30 Thermal balloon (Cavaterm) Amenorrhoea rate Brun 2006
36
1/97 3/196 5/96 5/194 49/96 120/194 Microwave (Microsulis) Heavy bleeding
rate
Cooper 2004
37
5/55 3/56 4/55 2/56 14/55 35/56 Laser (ELITT) Amenorrhoea rate Perino 2004
16
10/72 16/156 5/72 19/156 40/72 43/156 Cryoablation (HerOption) Heavy bleeding
rate
Duleba 2003
17
1/28 2/30 1/28 1/30 13/28 10/30 Thermal balloon (Cavaterm) Amenorrhoea rate Hawe 2003
38
13/58* 15/75* 19/55 23/74 4/55 6/74 Thermal balloon
(Thermachoice)
Heavy bleeding
rate
Van
Zon-Rabelink
2003
39
5/82 11/154 10/82 14/154 29/82 63/154 Biploar radio frequency
(NovaSure)
Heavy bleeding
rate
Cooper 2002
14
14/38 7/37 NA NA NA NA Thermal balloon (Cavaterm) Satisfaction rate Pellicano 2002
40
NA NA 12/83 31/172 43/83 65/172 Free fluid (BEI Medical
Systems)
Heavy bleeding
rate
Corson 2001
15
19/48 15/45 10/48 11/45 8/48 5/45 Thermal balloon
(Thermachoice)
Heavy bleeding
rate
Soysal 2001
41
NA NA 19/112 16/122 39/112 38/122 Thermal balloon (Vesta) Heavy bleeding
rate
Corson 2000
42
32/124 27/116 11/124 9/116 48/124 46/116 Microwave (Microsulis) Satisfaction rate Cooper 1999
12
1/116 5/122 13/117 18/122 32/117 18/122 Thermal balloon
(Thermachoice)
Heavy bleeding
rate
Meyer 1998
9
NA NA 0/10 0/10 3/10 4/10 Thermal balloon (Cavaterm) Not stated Romer 1998
43
NA=not applicable (outcome not measured).
*Data from 24 months after randomisation but considered as 12 month data. All other data are follow-up data at 12 months after randomisation.
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RESEARCHTable 2| Amenorrhoea rate at 12 months: results from direct comparisons and network meta-analysis. Figures are odds ratios (95%
confidence intervals) for device in column compared with device in row. Odds ratio >1 indicate increased rate with device in column
Laser Free fluid Cryoablation Microwave
Bipolar radio
frequency Thermal balloon
First generation device
4.88 (2.17 to 11.00);
P<0.001†
0.57 (0.33 to 0.96);
P=0.03†
0.30 (0.17 to 0.55);
P<0.001†
1.28 (0.90 to 1.83);
P=0.2‡
1.27 (0.73 to 2.20);
P=0.4†
0.72 (0.52 to 1.01);
P=0.06*
Direct
4.36 (1.82 to 10.44);
P=0.002
0.62 (0.34 to 1.13); P=0.1 0.35 (0.17 to 0.75);
P=0.01
1.14 (0.73 to 1.79);
P=0.5
1.73 (1.07 to 2.78);
P=0.03
0.69 (0.49 to 0.97);
P=0.03
Network
Thermal balloon
NA NA NA 1.13 (0.70 to 1.82);
P=0.6†
4.56 (2.24 to 9.26);
P<0.001*
— Direct
6.34 (2.50 to 16.07);
P<0.001
0.91 (0.48 to 1.73); P=0.7 0.51 (0.23 to 1.17);
P=0.1
1.66 (1.01 to 2.71);
P=0.05
2.51 (1.53 to 4.12);
P<0.001
— Network
Bipolar radio frequency
NA 0.36 (0.18 to 0.73);
P=0.005†
NA NA — — Direct
2.52 (0.95 to 6.71); P=0.06 0.36 (0.19 to 0.67);
P=0.004
0.20 (0.09 to 0.49);
P=0.002
0.66 (0.36 to 1.21);
P=0.2
— — Network
Microwave
NA NA NA — — — Direct
3.82 (1.46 to 10.01);
P=0.009
0.55 (0.27 to 1.13); P=0.09 0.31 (0.13 to 0.74);
P=0.01
— — — Network
Cryoablation
NA NA — — — — Direct
12.37 (3.96 to 38.59);
P<0.001
1.77 (0.69 to 4.58); P=0.2 — — — — Network
Free fluid
NA — — — — — Direct
6.98 (2.48 to 19.69);
P<0.001
— — — — — Network
NA=not available.
*I
2=0%.
†I
2=not applicable, only one study in comparison.
‡I
2=17%.
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RESEARCHTable 3| Heavy bleeding rate at 12 months: results from direct comparisons and network meta-analysis. Figures are odds ratios (95%
confidence intervals) for device in column compared with device in row. Odds ratio >1 indicate increased rate with device in column
Laser Free fluid Cryoablation Microwave
Bipolar radio
frequency Thermal balloon
First generation device
0.47 (0.08 to 2.69); P=0.4† 1.30 (0.63 to 2.69); P=0.5† 1.86 (0.67 to 5.19);
P=0.2†
0.71 (0.34 to 1.50);
P=0.4*
0.72 (0.30 to 1.70);
P=0.5†
0.97 (0.66 to 1.41);
P=0.9*
Direct
0.39 (0.07 to 2.09); P=0.3 1.37 (0.74 to 2.51); P=0.3 1.55 (0.63 to 3.81);
P=0.3
0.59 (0.32 to 1.09);
P=0.09
0.95 (0.56 to 1.62);
P=0.8
0.98 (0.69 to 1.39);
P=0.9
Network
Thermal balloon
NA NA NA 0.76 (0.25 to 2.32);
P=0.6†
1.02 (0.46 to 2.29);
P=1.0*
— Direct
0.41 (0.07 to 2.27); P=0.3 1.80 (0.90 to 3.57); P=0.09 1.62 (0.62 to 4.24);
P=0.3
0.62 (0.32 to 1.18);
P=0.1
0.82 (0.47 to 1.44);
P=0.5
— Network
Bipolar radio frequency
NA 4.88 (1.32 to 18.11);
P=0.02†
NA NA — — Direct
0.50 (0.09 to 2.89); P=0.4 2.19 (1.07 to 4.50); P=0.03 1.98 (0.70 to 5.60);
P=0.2
0.75 (0.34 to 1.66);
P=0.5
— — Network
Microwave
NA NA NA — — — Direct
0.66 (0.11 to 3.96); P=0.6 2.91 (1.23 to 6.88); P=0.02 2.63 (0.89 to 7.78);
P=0.08
— — — Network
Cryoablation
NA NA — — — — Direct
0.25 (0.04 to 1.70); P=0.2 1.11 (0.37 to 3.29); P=0.9 — — — — Network
Free fluid
NA — — — — — Direct
0.23 (0.04 to 1.36); P=0.1 — — — — — Network
NA=not available.
*I
2=0%.
†I
2=not applicable, only one study in comparison.
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RESEARCHTable 4| Dissatisfaction rate at 12 months: results from direct comparisons and network meta-analysis. Figures are odds ratios (95%
confidence intervals) for device in column compared with device in row. Odds ratio >1 indicate increased rate with device in column
Laser Free fluid Cryoablation Microwave Bipolarradiofrequency Thermal balloon
First generation device
0.57 (0.13 to 2.49); P=0.5† NA 0.71 (0.30 to 1.65);
P=0.4†
0.90 (0.51 to 1.60);
P=0.7‡
1.18 (0.40 to 3.53);
P=0.8†
0.80 (0.50 to 1.27);
P=0.3*
Direct
0.54 (0.12 to 2.43) P=0.4 3.14 (0.66 to 14.83); P=0.1 0.93 (0.59 to 1.47);
P=0.7
0.93 (0.59 to 1.47);
P=0.7
0.51 (0.25 to 1.01);
P=0.05
0.91 (0.61 to 1.36);
P=0.6
Network
Thermal balloon
NA NA NA 1.07 (0.61 to 1.86);
P=0.8†
0.39 (0.16 to 0.91);
P=0.03‡
— Direct
0.59 (0.12 to 2.78); P=0.5 2.66 (0.55 to 12.96); P=0.2 0.79 (0.31 to 2.05);
P=0.6
1.02 (0.65 to 1.60);
P=0.9
0.56 (0.28 to 1.09);
P=0.09
— Network
Bipolar radio frequency
NA 9.40 (1.14 to 77.18);
P=0.04†
NA NA — — Direct
1.06 (0.20 to 5.51); P=0.9 4.79 (1.07 to 21.48);
P=0.04
1.42 (0.47 to 4.29);
P=0.5
1.83 (0.85 to 3.95);
P=0.1
— — Network
Microwave
NA NA NA — — — Direct
0.58 (0.12 to 2.79); P=0.5 2.62 (0.52 to 13.23); P=0.2 0.78 (0.29 to 2.07);
P=0.6
— — — Network
Cryoablation
NA NA — — — — Direct
0.74 (0.13 to 4.25); P=0.7 3.37 (0.56 to 20.39); P=0.2 — — — — Network
Free fluid
NA — — — — — Direct
0.22 (0.03 to 1.95); P=0.2 — — — — — Network
NA=not available
*I
2=4%
†I
2=not applicable, only one study in comparison.
‡I
2 =0%.
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RESEARCHFigures
Fig 1 Study selection process for systematic review and network meta-analysis of second generation endometrial destruction
techniques for heavy menstrual bleeding
Fig 2 Network of studies evaluating second generation endometrial destruction devices for treatment of heavy menstrual
bleeding. Number of women randomised to second generation treatment are shown in parentheses
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RESEARCHFig 3 Amenorrhoea rate at 12 months from network meta-analysis (odds ratio and 95% confidence intervals). Results reflect
those in table 2 (*indicates reversed ratios so all are pointing in direction of increased amenorrhoea rate). Only results with
P≤0.05 are shown
Fig 4 Trends in types of endometrial ablation procedures performed in England, 2004-11 (data from hospital episode
statistics)
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